[Immuno-Oncology Newsletter - Edition 8] Next-Gen Oncology: From Targeted Therapies to Translational Tools

Immuno-Oncology Insights: Empowering Translational Research

At Tebubio, we strive to bring you timely and relevant insights into the trends shaping the life sciences landscape. To open this edition, we’re turning the spotlight on a therapeutic approach that’s capturing growing attention across research and industry: Antibody-Drug Conjugates (ADCs).

ADCs are redefining the boundaries of oncology by combining the precision of monoclonal antibodies with the cytotoxic power of chemotherapeutic agents. The potential is considerable — but so are the challenges. With over 1,100 candidates in development and fewer than 30% reaching clinical stages, the field demands continuous innovation in target selection, linker chemistry, and payload design. Meanwhile, major deals and investments are reinforcing the strategic value of ADCs in today’s biopharma landscape. 

As the field evolves, the true measure of success will lie in turning scientific ingenuity into meaningful clinical outcomes for patients.

_{(Source: ​MabDesign.fr​ , ADCs : antibodies and cytotoxic molecules united against tumours. Published on April 28th 2025.)}

Upcoming Webinar

Empowering the Development of TCR-T and CAR-T Cells for Adoptive Cell Therapy.

Join us for an expert-led session exploring tools and strategies to accelerate the development of TCR-T and CAR-T cells for adoptive cell therapy. Discover how to enhance cell activation, expansion, and functional profiling with ready-to-use reagents and in vitro solutions.

Don’t miss this opportunity to stay ahead in cellular immunotherapy research!

Date: June 5th

Time: 3 p.m. BST

Time: 4 p.m. CEST

Tebubio Contract Research Services

Accelerate Your Immuno-Oncology Programs with In Vitro Modelling Expertise.

Advancing immuno-oncology drug development requires models that reflect real biological complexity—especially when evaluating mRNA-based therapeutics or delivery systems. 

Our Contract Research Services (CRS) offer tailored in vitro assay development and cell-based screening platforms designed to support the evaluation of immune activation, cytokine responses, and transfection efficiency. 

Whether you're working with novel RNA constructs, targeting tumor–immune interactions, or optimising delivery strategies, our experts help you design and execute reliable, high-content assays—so you generate meaningful data, faster.

Stimulus solutions

Fast-track your oncology screens with ready-to-use compound antibodies.

Looking for a high-impact starting point for your next anti-cancer assay? The Anti-Cancer Compound Library from TargetMol offers over 500 bioactive molecules with known effects on key cancer pathways. 

From apoptosis to angiogenesis inhibition, this library is your shortcut to focused, high-confidence screening.

Models solutions

ELISA-Based Tools to Measure Cellular PARylation.

Understanding PARylation dynamics is crucial in cancer biology, especially when evaluating DNA damage response or PARP inhibitor efficacy. 

Discover user-friendly ELISA-based methods from our partner BPS Bioscience that offer a reliable alternative to traditional western blotting, ideal for streamlining your immuno-oncology workflows.

Analysis solutions

Simplify Your Apoptosis Assays – Without Compromising Accuracy

Struggling with inconsistent apoptosis detection or time-consuming protocols? The Annexin V Plate Assay Kit from Dojindo is designed with your workflow in mind. Achieve robust, reproducible results—quickly and efficiently—with a straightforward plate-based format that fits seamlessly into high-throughput routines. 

No flow cytometry. No hassle. Just reliable data, every time.

We facilitate Life Sciences Research daily, advancing Science for a brighter future with comprehensive biological solutions from top global suppliers to accelerate your research projects.

If you lack time or expertise, our CRS team can support you with mRNA production, cell line engineering, protein production, cellular studies, and biomarker analysis.

With Tebubio, concentrate your efforts and accelerate what’s most important to you: your research.

Stay Ahead in Immuno-Oncology

Subscribe to our monthly newsletter for the latest breakthroughs, expert insights, and exclusive updates in immuno-oncology.